Nano-Technology Enabled Repositioning of Cannabinoids for Treating NAFLD
Obesity is a catalyst for numerous conditions; the most notable is non-alcoholic fatty liver disease (NAFLD), for which currently no drug therapy has been approved by the FDA and EMA for its treatment. The endocannabinoid (eCB) sy...
Obesity is a catalyst for numerous conditions; the most notable is non-alcoholic fatty liver disease (NAFLD), for which currently no drug therapy has been approved by the FDA and EMA for its treatment. The endocannabinoid (eCB) system triggers the development of obesity and its related comorbidities, specifically NAFLD. eCBs, via activating the cannabinoid-1 receptors (CB1Rs) in the liver, increase hepatic glucose production, insulin resistance, and de novo lipogenesis, and decrease fatty acid oxidation. Accordingly, globally-acting CB1R blockers improve these parameters both in rodents and humans. However, owing to their neuropsychiatric side effects, they were withdrawn from the market and are no longer available for clinical use. NANOFLD aims to revive their clinical development and testing by utilizing an innovative nanometric drug delivery system for the hepatic targeting of globally-acting CB1R blockers for treating NAFLD. In the framework of my ERC-StG grant, CaNanoBinoids, my team successfully encapsulated the first-in-class CB1R blocker, rimonabant, in nanoparticles (NPs), tested their stability, efficacy, and potency, and demonstrated their therapeutic potential in ameliorating NAFLD, insulin resistance, and dyslipidemia in mice. To further translate our findings into clinical practice, the present PoC application builds on and expands this avenue of research by achieving several necessary steps including biodistribution, hepatic cellular fate, and PK studies of our novel nanometric drug delivery system. Importantly, we have secured the IP, conducted a specific market assessment, targeted regulatory constraints, implemented a business development plan, consulted with professionals in the field, and developed contacts with industry. When this project is completed, we expect to have introduced a unique innovation to treat NAFLD and its metabolic abnormalities, further promoting the idea to clinically test CB1R blockers encapsulated in NPs against NAFLD.ver más
02-11-2024:
Generación Fotovolt...
Se ha cerrado la línea de ayuda pública: Subvenciones destinadas al fomento de la generación fotovoltaica en espacios antropizados en Canarias, 2024
01-11-2024:
ENESA
En las últimas 48 horas el Organismo ENESA ha otorgado 6 concesiones
01-11-2024:
FEGA
En las últimas 48 horas el Organismo FEGA ha otorgado 1667 concesiones
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.